rethinkPeptides Search
Menu
Research citation

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.

The Journal of clinical endocrinology and metabolism, 103(8), 2949-2957

Citation

Bone, Henry G; Cosman, Felicia; Miller, Paul D; Williams, Gregory C; Hattersley, Gary; Hu, Ming-Yi; Fitzpatrick, Lorraine A; Mitlak, Bruce; Papapoulos, Socrates; Rizzoli, René; Dore, Robin K; Bilezikian, John P; Saag, Kenneth G. (2018). ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.. The Journal of clinical endocrinology and metabolism, 103(8), 2949-2957. https://doi.org/10.1210/jc.2018-00163